All Professionals
Overview
James Huie is a San Francisco-based partner in the Securities & Capital Markets practice at Paul Hastings.
James advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience representing venture capital firms and other investors in private equity and debt financings.
His practice focuses on advising early and late-stage start-ups throughout all stages of their lifecycle, along with numerous venture investors. His clients comprise the full range of the start-up ecosystem, from one-person companies to unicorns preparing for public offerings.
Education
- Santa Clara University School of Law, J.D. (Senior Comments Editor, Santa Clara Computer & High Technology Law Journal), 2005
- University of California, Berkely, B.A., Molecular Cell Biology (with distinction, emphasis in Biochemistry), 2002
Representations
- Umoja Biopharma in its $210 million Series B financing led by Softbank Vision Fund and Cormorant Asset Management
- Noah Medical in its $150 million Series B financing led by Softbank Vision Fund and Prosperity7 Ventures.
- Neptune Medical in its $97 million in its Series D financing led by Sonder Capital and Olympus Corporation, including the spinout of Jupiter Endovascular
- Foresight Diagnostics in its $59 million Series B financing led by Foresite Capital
- Avive Solutions in its $56 million financing led by Questa Capital, Laerdal Million Lives Fund, Catalyst Health Ventures and RC Capital
- Prolific Machines in its $55 million Series B financing led by The Ki Tua Fund, the venture arm of Fronterra Co-operative Group, Breakthrough Energy Ventures, Mayfield Ventures and SOSV
- Ceribell in its $53 million Series C financing led by Longitude Capital and TPG
- Noctrix Health in its $40 million Series C financing led by Sectoral Asset Management, OrbiMed and Treo Ventures
- Inquis Medical in its $40 million Series B financing led by Marshall Wace
- Atomic AI in its $35 million Series A financing led by Playground Global
- Adona Medical in its $33.5 million Series C financing led by Cormorant Asset Management and TCP Health Ventures
- Galatea Bio in its $25 million financing led by F-Prime, Helios Digital ventures, AME Cloud and Alexandria Properties
- Advanced Cardiac Therapeutics in its option for acquisition by Abbott Cardiovascular
- Cephea Valve Technologies in its acquisition by Abbott Cardiovascular
- Rewrite Therapeutics in its acquisition by Intellia Therapeutics
- Replace Therapeutics in its acquisition by Tome Biosciences
- U-Systems in its acquisition by GE Healthcare
- Acclarent in its acquisition by Ethicon
- SurgRx in its acquisition by Ethicon Endo-Surgery
- Arrinex in its acquisition by Stryker Corporation
- Epix Therapeutics in its acquisition by Medtronic
- Eat24hours in its acquisition by Yelp
- Hopthru in its acquisition by Swiftly
- Tencent in its acquisition of Riot Games
Engagement & Publications
- “FoodTech White Paper: 2020 Trends in Venture Capital Financings,” March 2021